<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03116555</url>
  </required_header>
  <id_info>
    <org_study_id>CLOG0103</org_study_id>
    <nct_id>NCT03116555</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA</brief_title>
  <official_title>A Prospective, Multicenter Clinical Study of Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junctional Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The People's Hospital of Liaoning Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anshan Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Benxi central hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Tumor Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Panjin central hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin University Sino-Japanese Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After failure of first-line therapy, single agent of irinotecan is used as second line
      treatment in locally advanced or metastatic gastric or gastroesophageal junctional
      adenocarcinoma. The purpose of this study is to evaluate it there will be more benefit with
      irinotecan plus apatinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer is the fourth most common cancer in the world and the second cancer cause.
      China has a high incidence of gastric cancer, accounting for 47% of the global total. System
      chemotherapy is the main treatment of advanced gastric cancer. After failure of first-line
      therapy, single agent of irinotecan is used as second line treatment in locally advanced or
      metastatic gastric or gastroesophageal junctional adenocarcinoma. The purpose of this study
      is to evaluate it there will be more benefit with irinotecan plus apatinib.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival [PFS]</measure>
    <time_frame>5-6 months</time_frame>
    <description>Progression Free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival [OS]</measure>
    <time_frame>12-15 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate [ORR]</measure>
    <time_frame>12-15 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate [DCR]</measure>
    <time_frame>12-15 months</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence and Degree of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>12-15 months</time_frame>
    <description>Incidence and Degree of Treatment-Emergent Adverse Events</description>
  </other_outcome>
  <other_outcome>
    <measure>Performance Status [WHO-ECOG]</measure>
    <time_frame>12-15 months</time_frame>
    <description>Performance Status</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life [WHO-QOL]</measure>
    <time_frame>12-15 months</time_frame>
    <description>Quality of Life</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Metastatic Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Irinotecan plus apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan: 180mg/m2, ivgtt,given on the first day; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day).
Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irinotecan: 180mg/m2, ivgtt,given on the first day; Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).</description>
    <arm_group_label>Irinotecan plus apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan was used as second line treatment with AGC</description>
    <arm_group_label>Irinotecan plus apatinib</arm_group_label>
    <arm_group_label>Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age：18-70，female or male.

          2. Pathologically diagnosed local advanced or metastatic stomach or gastroesophageal
             junction with adenocarcinoma, at least one measurable objective tumor lesion by spiral
             CT examination（according to RECIST 1.1）.

          3. First-line application of fluorouracil-based chemotherapy failed (treatment failure
             definition: toxic side effects can not tolerate the progress of the disease during
             treatment or recurrence after treatment); Note:(1) Time of first-line treatment for
             subjects with advanced tumour must more than 1 cycles;(2) Adjuvant/neoadjuvant therapy
             was allowed; adjuvant/neoadjuvant therapy will be considered as a first-line treatment
             if disease recurrence during treatment or after less than 24 weeks.

          4. UGT1A1*28(6/6) and *6(G/G) ,or UGT1A1*28(6/6) and *6(G/A),or UGT1A1*28(6/7) and
             *6(G/G).

          5. ECOG performance status 0-1.

          6. satisfactory main organ function，laboratory test must meet the following criteria: (1)
             blood routine examination standards to meet: A. HB≥90g/L; B. ANC≥1.5×109/L; C.
             PLT≥90×109/L; (2) biochemical tests to meet the following criteria: A. Total
             bilirubin≤1.5 times the upper limit of normal (ULN) B. ALT and AST≤2.5ULN; C. Serum
             Cr≤1ULN, endogenous creatinine clearance&gt; 60ml/min (Cockcroft-Gault formula)

          7. The international normalized ratio (INR) ≤ 1.5 and some prothrombin time (PPT or APTT)
             ≤ 1.5ULN within 7 days before participating.

          8. Expected survival≥3 months;

          9. Signed informed consent (ICF) before admission;

         10. Women of childbearing age must undergo a pregnancy test (serum or urine) within 7 days
             prior to enrollment and have a negative result and are willing to use appropriate
             methods for contraception at 8 weeks after the trial and at the end of the last test.
             For men, contraception should be used for surgical sterilization, or agreed to use the
             appropriate method 8 weeks after the trial and the last given test drug.

        Exclusion Criteria:

          1. Hypersensitivity to apatinib, irinotecan or excipients.

          2. More than one chemotherapy regimen was treated after progression of gastric cancer
             (except for adjuvant/neoadjuvant chemotherapy with more than 24 weeks of clearance).

          3. Prior exposure to irinotecan.

          4. Prior exposure to irinotecan VEGFR inhibitors, such as apotinib, sorafenib, sunitinib.

          5. Another primary tumor in patients, except for: systematically treatment non-melanoma
             skin cancer, effectively treatment cervical carcinoma in situ, or other effectively
             treatment tumors wtih no recurrence for more than 5 years.

          6. Anti neoplastic cytotoxic drugs, biological drugs (such as monoclonal antibodies),
             immunotherapy (such as interleukin 2 or interferon), or other research drugs have been
             use within 4 weeks before participating.

          7. Uncontrolled hypertention with systolic blood pressure&gt; 140 mmHg or diastolic blood
             pressure&gt; 90 mmHg, grade I or more coronary heart disease, grade I arrhythmia
             (including QTc interval: male&gt; 450 ms, female&gt; 470 ms) and grade I cardiac
             insufficiency.

          8. Urine routine urinary protein ≥ ++, or 24 hours urine protein ≥ 1g.

          9. Any toxicity more than 1 grade(according to CTCAE) caused by previous treatment,
             except hair loss.

         10. Occasional artery/venous thrombosis events, such as cerebrovascular accident
             (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep
             vein thrombosis and pulmonary embolism occurred within 12 months before participation;

         11. Intestinal obstruction occurred 4 weeks before participation.

         12. Patients who underwent major surgery 4 weeks prior to initiation of treatment. The
             patient must be cured from any major surgery.

         13. Patients who are considered to have a greater risk of medical care due to a serious,
             uncontrollable disease, non-metastatic systemic disease or active, uncontrollable
             infection. Some examples include, but not exclusively, uncontrolled ventricular
             arrhythmias, recent (3 months) myocardial infarction, uncontrollable epilepsy
             seizures, unstable spinal cord compression, superior vena cava syndrome, HRCT tips
             Bilateral interstitial lung disease or any mental illness that may obstruct informed
             consent.

         14. Immunocompromised patients, for example, serological tests suggest that human
             immunodeficiency virus (HIV) is positive.

         15. Pregnant or lactating women.

         16. Have a variety of factors that affect oral medication (such as unable to swallow,
             nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.).

         17. Patients with clear gastrointestinal bleeding tendencies. Including the following:
             there is black stool, hematemesis history in 2 months can not be grouped; For patient
             with fecal occult blood (+) and the primary tumor of the stomach tumor not surgical
             resected, if the center of the main investigators believe that there is possible
             occurrence of gastrointestinal bleeding,the patient can not be grouped.

         18. Ascites or pleural effusion requiring clinical treatment of persistent.

         19. A history or evidence of hereditary hemorrhagic physical or coagulopathy that
             increases the risk of bleeding.

         20. With central nervous system metastasis with symptoms.

         21. With Gilbert syndrome.

         22. Participated in other drug clinical trials in four weeks.

         23. Researchers believe that they are not suitable for inclusion.

         24. Patients who had bone metastases and had undergone palliative radiotherapy
             (radiotherapy&gt; 5% bone marrow area) within 4 weeks prior to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YunPeng Liu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of China Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YunPeng Liu, PhD</last_name>
    <phone>86-24-83282312</phone>
    <email>cmuliuyunpeng@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiujuan Qu, PhD</last_name>
    <phone>86-24-83282542</phone>
    <email>qu_xiujuan@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunpeng Liu, PhD</last_name>
      <phone>86-24-83282312</phone>
      <email>cmuliuyunpeng@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiujuan Qu, PhD</last_name>
      <phone>86-24-83282542</phone>
      <email>qu_xiujuan@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.</citation>
    <PMID>21296855</PMID>
  </results_reference>
  <results_reference>
    <citation>Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. doi: 10.1056/NEJMoa073149.</citation>
    <PMID>18172173</PMID>
  </results_reference>
  <results_reference>
    <citation>Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E, Tonini G, Catalano G. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer. 2008 Nov 4;99(9):1402-7. doi: 10.1038/sj.bjc.6604732.</citation>
    <PMID>18971936</PMID>
  </results_reference>
  <results_reference>
    <citation>Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013 Sep 10;31(26):3219-25. doi: 10.1200/JCO.2013.48.8585. Epub 2013 Aug 5.</citation>
    <PMID>23918952</PMID>
  </results_reference>
  <results_reference>
    <citation>Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 Oct;47(15):2306-14. doi: 10.1016/j.ejca.2011.06.002.</citation>
    <PMID>21742485</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2017</study_first_posted>
  <last_update_submitted>November 5, 2017</last_update_submitted>
  <last_update_submitted_qc>November 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Yunpeng Liu</investigator_full_name>
    <investigator_title>Director of Department of Medical Oncology，The First Hospital of China Medical University</investigator_title>
  </responsible_party>
  <keyword>Apatinib</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Second-line</keyword>
  <keyword>Metastatic Gastric Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

